Finally, to evaluate whether IRF4 signaling can be exploited therapeutically in the ALCL context, we tested the sensibility of several ALCL cells to IMiDs, such as lenalidomide and pomalidomide, that indirectly downregulate IRF4 [34,36,52]. Here, IRF4 is linked to anaplastic large cell lymphoma.